Hyloris PharmaceuticalsLTS:0AB6 63 Gross Margin % is 94.01% as of Dec. 2025, which is 5% above its 10-year median of 89.56. GuruFocus rates LTS:0AB6 with a GF Score™ of 63/100 and a GF Value™ of €9.52 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 734 Biotechnology companies, Hyloris Pharmaceuticals ranks better than 92.37% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Hyloris Pharmaceuticals had a gross margin of 94.01% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Hyloris Pharmaceuticals Gross Margin % Related Terms
Hyloris Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0AB6 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Hyloris Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyloris Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Hyloris Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Hyloris Pharmaceuticals (LTS:0AB6) has a Gross Margin % of 94.01% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Hyloris Pharmaceuticals and its competitors. This is near median its historical median of 89.56. Over the past decade, Hyloris Pharmaceuticals' Gross Margin % has ranged from 17.14 to 97.32. According to the industry distribution chart, Hyloris Pharmaceuticals ranks #56 out of 734 companies in the Biotechnology industry, placing it in the top 7.6%.
Is Hyloris Pharmaceuticals' Gross Margin % too high?
Hyloris Pharmaceuticals' current Gross Margin % of 94.01% is near median its 10-year median of 89.56. Over the past 10 years, this metric has ranged from a low of 17.14 to a high of 97.32. The Biotechnology industry median Gross Margin % is 60.80. Hyloris Pharmaceuticals' value of 94.01% is 54.6% above this industry median. Based on the distribution chart, Hyloris Pharmaceuticals ranks #56 out of 734 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hyloris Pharmaceuticals has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hyloris Pharmaceuticals ranks #56 out of 734 companies for Gross Margin %. This places Hyloris Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.80. Hyloris Pharmaceuticals' value of 94.01% is 54.6% above this benchmark. Historically, Hyloris Pharmaceuticals' own Gross Margin % has ranged from 17.14 to 97.32 over the past decade. While the company's 10-year median is 89.56 vs. the industry median of 60.80, Hyloris Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.80, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hyloris Pharmaceuticals's current Gross Margin % of 94.01% is 54.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Hyloris Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyloris Pharmaceuticals's current Gross Margin % is 94.01%, which is near median its own 10-year median of 89.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (LTS:0AB6) is currently considered Possible Value Trap. The stock's GF Value™ is €9.52, compared to a current price of €4.64 — trading 51.3% below its estimated fair value. The current Gross Margin % is 94.01%, which is near median its 10-year median of 89.56 and 54.6% above the Biotechnology industry median of 60.80. Hyloris Pharmaceuticals' overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current Gross Margin % is 94.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.64 is trading 51.3% below its estimated GF Value™ of €9.52.
GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.
Key valuation signals for LTS:0AB6:
Gross Margin %: 94.01% (near median its 10-year median of 89.56)
GF Value™: €9.52 vs. price of €4.64 (51.3% below fair value)
Industry Position: 54.6% above the Biotechnology median (#56 of 734)
No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
63GF Score
Get the complete analysis for LTS:0AB6
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0AB6 has been successfully added to your 
